Capricor Therapeutics Reports 3-Year Efficacy Results From HOPE-2 Open Label Extension Study Of CAP-1002 In DMD
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics announced positive 3-year results from the HOPE-2 open-label extension study of CAP-1002 for treating Duchenne muscular dystrophy (DMD). The study showed significant benefits in skeletal muscle function and cardiac function, with a well-tolerated safety profile. These results were shared with the FDA and will be presented at the upcoming PPMD Annual Conference.
June 04, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics reported positive 3-year results from the HOPE-2 study of CAP-1002 for DMD, showing significant benefits in muscle and cardiac function. The results were shared with the FDA and will be presented at the PPMD Annual Conference.
The positive 3-year results from the HOPE-2 study indicate significant benefits in muscle and cardiac function for DMD patients treated with CAP-1002. This news is likely to boost investor confidence and positively impact the stock price of Capricor Therapeutics in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100